New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Weight Management in Women of Reproductive Age

Jarrod Warner & Irene Schneider

Jarrod Warner & Irene Schneider

New Spirometry Standards: Key Changes for Clinical Practice

A/Prof Alberto Pinzon Charry

A/Prof Alberto Pinzon Charry

Food Allergy Prevention

A/Prof Daryl Cheng

A/Prof Daryl Cheng

Protecting Young Lungs – Paediatric Insights into RSV

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970